Welcome to our dedicated page for International Flavors&Fragranc news (Ticker: IFF), a resource for investors and traders seeking the latest updates and insights on International Flavors&Fragranc stock.
International Flavors & Fragrances Inc. reports developments across flavors, fragrances, food ingredients, health and biosciences for customers in food, beverage, personal care, home care, pet health and related markets. News frequently covers ingredient innovation, application labs and natural-extraction capabilities, including vanilla work in Madagascar and LMR Naturals in perfumery, cosmetics and flavors.
Company updates also address probiotics and bioscience products such as HOWARU Pet and PureStrong, nutrition claims tied to soy protein, quarterly earnings releases, dividends, and other capital or financial disclosures.
IFF (NYSE:IFF) opened a 650-square-meter Vanilla Innovation Center in Toamasina, Madagascar, near major vanilla-growing areas. The site unites lab analysis, extraction, flavor creation, application development and a research greenhouse, aiming to improve vanilla quality, traceability, sustainability and speed-to-market by innovating directly at origin.
LMR Naturals (NYSE: IFF) will present four new LMR Hearts at SIMPPAR in Grasse on May 26–27, 2026, showcasing Lavandin Heart France, Armoise Heart Morocco, Ylang Heart Madagascar and Geranium Heart Egypt.
The launch highlights LMR’s end-to-end stewardship: long-term sourcing, sustainable agriculture, precision extraction (molecular distillation, fractionation, CO₂) and a new Domaine des Naturals experimental field in Grasse.
IFF (NYSE: IFF) reported Q1 2026 results: net sales $2.74B (reported -4%; comparable currency neutral +3%), adjusted operating EBITDA $568M (margin 20.7%), and adjusted EPS ex amortization $1.25. Cash from operations was $257M and free cash flow $92M. The company reaffirmed full-year 2026 guidance: sales $10.5–10.8B and adjusted operating EBITDA $2.05–2.15B, and is running a disciplined sale process for its Food Ingredients business.
International Flavors & Fragrances (NYSE: IFF) said its Board declared a regular quarterly cash dividend of $0.40 per share, payable July 10, 2026 to shareholders of record as of June 18, 2026.
Contact details for media and investor relations were provided.
IFF (NYSE: IFF) will release first quarter 2026 earnings after market close on May 5, 2026. The management team will host a live webcast on May 6, 2026 at 9:00 a.m. ET to discuss results and outlook. Investors can access the webcast and slides at ir.iff.com; a replay will be available.
Contact details for media and investor relations were provided for follow-up.
International Flavors & Fragrances (NYSE: IFF) will showcase wellness-driven, sustainable scent and bioscience innovations at In-Cosmetics Global 2026, April 14–16 at Paris Expo Porte de Versailles. Highlights include METAMOOD™, METASLEEP™, LMR Active Essences, AURIST™ AGC, GENENCARE® exhibits, and a technical seminar on April 15.
Attendees can experience sensory bars, live sessions, and formulation demonstrations focused on emotional and physical wellness benefits and ecofriendly extraction and biotech-enabled ingredients.
IFF (NYSE: IFF) launched PureStrong™ on April 2, 2026, a probiotic formulated specifically for canine digestive health using a single targeted strain of Limosilactobacillus reuteri sourced from healthy dogs. According to the company, a controlled study showed improved digestive markers, firmer stools and better diet tolerance.
PureStrong™ is part of IFF’s HOWARU Pet portfolio and is developed for powders, capsules, tablets and sticks to address the growing $3.2 billion U.S. pet supplement market.
IFF (NYSE: IFF) announced that Food Standards Australia New Zealand has accepted a heart health claim for isolated soy protein, allowing products in Australia and New Zealand to link soy protein to healthy blood cholesterol levels.
Under the permission, foods delivering a daily intake of 20–25 grams of isolated soy protein, consumed as part of a balanced diet, may carry the claim. The approval follows multi‑year research and aligns Australia and New Zealand with 11 other countries recognizing the soy protein–heart health link.
IFF (NYSE: IFF) is expanding its Latin America capabilities with a new fermentation‑based enzyme production hub in Arroyito, Argentina, and a household care application laboratory at its Innovation Center in Brazil, announced March 10, 2026. These investments aim to improve local enzyme production, speed, reliability and regionally relevant solutions across brewing, animal nutrition, biofuels and home care.
The initiatives bring initial biological‑stage enzyme production to the region and enable faster formulation testing under real regional conditions, reinforcing IFF Health & Biosciences’ multi‑decade commitment to Latin American growth.
IFF (NYSE: IFF) declared a regular quarterly cash dividend of $0.40 per share, payable on April 10, 2026 to shareholders of record as of March 20, 2026.
This announcement confirms IFF's continued distribution policy and provides a specific payment timeline and record date for investors.